Skip to Main Content

Japanese drugmaker Astellas said late Sunday it would acquire eye drug developer Iveric Bio for $5.9 billion, betting heavily on a prospective treatment for a form of vision loss that affects around 1 million people in the U.S.

Iveric had been competing with another biotech, Apellis Pharmaceuticals, to develop the first therapy for geographic atrophy, a disease of aging in which parts of the retina waste away, forming irreversible blind spots. Apellis’s drug, Syfovre, was approved in February, but the Food and Drug Administration is expected to rule on Iveric’s drug candidate by Aug. 19.

advertisement

Because of the size of the patient population and lack of alternatives, both therapies could become blockbusters.

STAT+ Exclusive Story

STAT+

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect

To submit a correction request, please visit our Contact Us page.